Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced today that its compensation committee granted an inducement stock option to Daniel Keefe, the company's recently-hired Commercial Director for the Western U.S. The grant, made on May 5, 2026, covers 17,000 shares of common stock at an exercise price of $3.20 per share, equal to the closing price on the grant date. The option vests over four years, with one-quarter vesting on the first anniversary and the remainder monthly thereafter, contingent on continued employment.
The appointment of Keefe and the accompanying inducement grant reflect Aclarion's strategic focus on expanding its commercial footprint in the Western U.S., a region seen as critical for driving adoption of its Nociscan platform. Nociscan is a cloud-based SaaS solution that uses magnetic resonance spectroscopy (MRS) and proprietary augmented intelligence algorithms to help physicians identify painful lumbar discs, addressing the chronic low back pain market. The company has reported triple-digit growth in Nociscan utilization, indicating increasing demand from healthcare providers.
“This expansion of our commercial team underscores the strong momentum behind Nociscan,” said a company spokesperson. “We are seeing rapid adoption as physicians recognize the value of noninvasively pinpointing pain sources, which can lead to more effective treatment strategies.” The inducement grant was structured under Nasdaq Listing Rule 5635(c)(4), which permits such grants as a material inducement for new hires without shareholder approval.
Chronic low back pain affects millions of Americans annually, and accurate diagnosis of pain-generating discs remains a challenge. Nociscan aims to fill this gap by providing objective biomarker data, potentially reducing reliance on invasive diagnostic procedures and improving surgical outcomes. The company’s technology has been supported by clinical evidence and is increasingly being integrated into clinical workflows.
As Aclarion scales its commercial operations, the addition of a dedicated director for the Western U.S. is expected to enhance customer engagement and support in a key market. The company continues to invest in sales and marketing to capitalize on the growing demand, with utilization rates rising sharply in recent quarters.
For more information about Aclarion and Nociscan, visit www.aclarion.com. The latest news and updates relating to $ACON are available in the company’s newsroom at https://tinyurl.com/aconnewsroom.
